Summary
1.60 -0.02(-1.23%)09/06/2024
Lexicon Pharmaceuticals Inc (LXRX)
Lexicon Pharmaceuticals Inc (LXRX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.31 | -7.78 | -2.44 | -8.57 | -26.94 | -1.84 | 15.94 | -98.78 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.60 | |
| Open | 1.62 | |
| High | 1.66 | |
| Low | 1.56 | |
| Volume | 3,349,693 | |
| Change | -0.00 | |
| Change % | -0.31 | |
| Avg Volume (20 Days) | 2,588,556 | |
| Volume/Avg Volume (20 Days) Ratio | 1.29 | |
| 52 Week Range | 0.92 - 3.73 | |
| Price vs 52 Week High | -57.10% | |
| Price vs 52 Week Low | 73.91% | |
| Range | -1.23 | |
| Gap Up/Down | -0.03 | |
Fundamentals | ||
| Market Capitalization (Mln) | 582 | |
| EBIDTA | -185,355,008 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -0.1400 | |
| WallStreet Target Price | 5.25 | |
| Book Value | 1.1730 | |
| Earnings Per Share | -0.8300 | |
| EPS Estimate Current Quarter | -0.2000 | |
| EPS Estimate Next Quarter | -0.1800 | |
| EPS Estimate Current Year | -0.7600 | |
| EPS Estimate Next Year | -0.6900 | |
| Diluted EPS (TTM) | -0.8300 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -40.1177 | |
| Return on asset (TTM) | -0.4008 | |
| Return on equity (TTM) | -1.0272 | |
| Revenue TTM | 2,310,000 | |
| Revenue per share TTM | 0.0100 | |
| Quarterly Revenue Growth (YOY) | 46.0830 | |
| Quarterly Earnings Growth (YOY) | -0.6340 | |
| Gross Profit (TTM) | -52,677,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.2098 | |
| Revenue Enterprise Value | 349.7711 | |
| EBITDA Enterprise Value | -2.5763 | |
| Shares | ||
| Shares Outstanding | 246,236,992 | |
| Shares Float | 99,981,971 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.49 | |
| Insider (%) | 1.69 | |
| Institutions (%) | 80.82 | |
09/03 16:00 EST - globenewswire.com
Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences
THE WOODLANDS, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lexicon management will participate in the following investor conferences taking place in September:
Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences
THE WOODLANDS, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lexicon management will participate in the following investor conferences taking place in September:
08/22 12:30 EST - zacks.com
Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
The FDA plans to hold an Advisory Committee meeting to give a recommendation for Lexicon's (LXRX) Zynquista (sotagliflozin) on Oct 31, 2024. Stock up.
Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
The FDA plans to hold an Advisory Committee meeting to give a recommendation for Lexicon's (LXRX) Zynquista (sotagliflozin) on Oct 31, 2024. Stock up.
08/14 13:35 EST - zacks.com
Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up
Lexicon (LXRX) announces a portfolio reprioritization plan to focus on reducing operational expenses and driving the growth of the commercial portfolio. Shares rise.
Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up
Lexicon (LXRX) announces a portfolio reprioritization plan to focus on reducing operational expenses and driving the growth of the commercial portfolio. Shares rise.
08/13 08:30 EST - globenewswire.com
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
Company to Focus on Targeted Promotion of INPEFA® in Heart Failure While Prioritizing Investment in the Potential Launch of ZYNQUISTA™
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
Company to Focus on Targeted Promotion of INPEFA® in Heart Failure While Prioritizing Investment in the Potential Launch of ZYNQUISTA™
08/07 08:00 EST - globenewswire.com
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists
THE WOODLANDS, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists being held August 9 - 12, 2024 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists
THE WOODLANDS, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists being held August 9 - 12, 2024 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
08/03 06:29 EST - seekingalpha.com
Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success
Lexicon Pharmaceuticals' launch of Inpefa continues to progress very slowly; prescriptions grew nearly 50% QoQ, but revenue is still below $2M and missing sell-side expectations. New leadership and cash reserves provide opportunities for Lexicon to improve commercial execution and drive revenue growth, and improved patient access and payer coverage are 2H'24 priorities. The company has resubmitted its application for Zynquista in Type 1 diabetes, a commercially significant opportunity, but one where regulatory and execution risk are still very present.
Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success
Lexicon Pharmaceuticals' launch of Inpefa continues to progress very slowly; prescriptions grew nearly 50% QoQ, but revenue is still below $2M and missing sell-side expectations. New leadership and cash reserves provide opportunities for Lexicon to improve commercial execution and drive revenue growth, and improved patient access and payer coverage are 2H'24 priorities. The company has resubmitted its application for Zynquista in Type 1 diabetes, a commercially significant opportunity, but one where regulatory and execution risk are still very present.
08/01 23:00 EST - seekingalpha.com
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2024 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2024 Earnings Conference Call August 1, 2024 5:00 PM ET Company Participants Lisa DeFrancesco – Head-Investor Relations and Corporate Strategy Mike Exton – Chief Executive Officer and Director Jeff Wade – President and Chief Financial Officer Tom Garner – Senior Vice President and Chief Commercial Officer Craig Granowitz – Senior Vice President and Chief Medical Officer Alan Main – Executive Vice President, Innovation and Chemical Sciences Conference Call Participants Yasmeen Rahimi – Piper Sandler Andrew Tsai – Jefferies Joe Pantginis – H.C. Wainwright Roanna Ruiz – Leerink Partners Operator Good day and welcome to Lexicon Pharmaceuticals Second Quarter 2024 Financial Results Conference Call.
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2024 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2024 Earnings Conference Call August 1, 2024 5:00 PM ET Company Participants Lisa DeFrancesco – Head-Investor Relations and Corporate Strategy Mike Exton – Chief Executive Officer and Director Jeff Wade – President and Chief Financial Officer Tom Garner – Senior Vice President and Chief Commercial Officer Craig Granowitz – Senior Vice President and Chief Medical Officer Alan Main – Executive Vice President, Innovation and Chemical Sciences Conference Call Participants Yasmeen Rahimi – Piper Sandler Andrew Tsai – Jefferies Joe Pantginis – H.C. Wainwright Roanna Ruiz – Leerink Partners Operator Good day and welcome to Lexicon Pharmaceuticals Second Quarter 2024 Financial Results Conference Call.
08/01 18:15 EST - zacks.com
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.22 per share a year ago.
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.22 per share a year ago.
07/30 08:49 EST - 247wallst.com
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
Penny stocks represent an interesting investment opportunity.
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
Penny stocks represent an interesting investment opportunity.
07/25 08:00 EST - globenewswire.com
Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.
Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.
07/17 12:17 EST - zacks.com
FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug
The FDA accepts Lexicon's (LXRX) resubmission seeking approval for sotagliflozin to treat adults with type 1 diabetes. A final decision is expected by Dec 20.
FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug
The FDA accepts Lexicon's (LXRX) resubmission seeking approval for sotagliflozin to treat adults with type 1 diabetes. A final decision is expected by Dec 20.
07/08 09:15 EST - globenewswire.com
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief executive officer and director of Lexicon.
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief executive officer and director of Lexicon.
06/21 09:25 EST - zacks.com
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
06/21 08:00 EST - globenewswire.com
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease
06/19 08:00 EST - globenewswire.com
Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP)
Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP)
06/14 08:00 EST - globenewswire.com
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific Sessions of the American Diabetes Association being held June 21 - 24, 2024 at the Orange County Convention Center in Orlando, Florida.
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific Sessions of the American Diabetes Association being held June 21 - 24, 2024 at the Orange County Convention Center in Orlando, Florida.
05/29 08:00 EST - businesswire.com
Lexicon Pharmaceuticals Selects Medidata to Help Advance First Non-Opioid Drug for Neuropathic Pain in Over Two Decades
NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, announced today that it has been selected by Lexicon Pharmaceuticals, Inc. to help advance PROGRESS, a Phase 2b study of LX9211 in diabetic peripheral neuropathic pain (DPNP), with the potential for LX9211 to become the first new, non-opioid drug approved for neuropathic pain in over two decades. Medidata will enable Lexicon to accelerate patient enrollm.
Lexicon Pharmaceuticals Selects Medidata to Help Advance First Non-Opioid Drug for Neuropathic Pain in Over Two Decades
NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, announced today that it has been selected by Lexicon Pharmaceuticals, Inc. to help advance PROGRESS, a Phase 2b study of LX9211 in diabetic peripheral neuropathic pain (DPNP), with the potential for LX9211 to become the first new, non-opioid drug approved for neuropathic pain in over two decades. Medidata will enable Lexicon to accelerate patient enrollm.
05/29 07:30 EST - globenewswire.com
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
THE WOODLANDS, Texas, May 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies Global Healthcare Conference. Jeff Wade, Lexicon's president and chief financial officer and Craig Granowitz, M.D., Ph.D., Lexicon's senior vice president and chief medical officer, will participate in a moderated discussion on Wednesday, June 5, 2024, at 3:00 pm ET.
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
THE WOODLANDS, Texas, May 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies Global Healthcare Conference. Jeff Wade, Lexicon's president and chief financial officer and Craig Granowitz, M.D., Ph.D., Lexicon's senior vice president and chief medical officer, will participate in a moderated discussion on Wednesday, June 5, 2024, at 3:00 pm ET.
05/14 07:00 EST - globenewswire.com
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1 Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1 Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1
05/09 07:30 EST - globenewswire.com
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon's president and chief financial officer, will make a company presentation on Tuesday, May 14, 2024, at 8:00 am PDT (11:00 am ET).
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon's president and chief financial officer, will make a company presentation on Tuesday, May 14, 2024, at 8:00 am PDT (11:00 am ET).